CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.

There is a constant war going on in your body. Working against you are viruses and cancer cells growing uncontrollably, ...

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...

Company AnnouncementTopline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

T cells are an elite fighting force of the immune system, seeking out and destroying diseased cells. But in a prolonged ...

For the immune system to effectively combat pathogens, antibody responses must be precisely controlled. So-called follicular ...

In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...